/ EN
Technical Support
| Contact Us
+1 312-802-6843
Technical Support
Contact Us
+1 312-802-6843
/ EN
Recover password
Professional Email
Verification Code
Send Code
Password
Anti-Phosphotyrosine Mouse mAb
Catalog Number: PTM-701
$ 290

Clone Number: 3B6

Host: Mouse Clonality: Monoclonal

Applications: WB

Reactivity: Human, Mouse, Rat

Synonyms: pTyr

Product Size
100 μl
Quantity

Shipping: Ambient temperature

Order online or send purchase order to info@ptmbio.com

FAQ Technical Support Protocols

General Information
Isotype IgG
Conjugate Unconjugated
Synonyms pTyr
UniProt ID

/

Immunogen
MW (kDa)
Specificity
Product Usage Information
Applications Dilution Recommended Species
WB 1:500 - 1:1000 All
Properties
Purity Protein G and immunogen affinity purified
Constituents PBS, Glycerol, BSA
Storage Store at -20°C. Avoid freeze/thaw cycles.
Stability Stable for 12 months from date of receipt/reconstitution.
Target Information

Background

Tyrosine phosphorylation is the addition of a phosphate group to the amino acid tyrosine on a protein. It is one of the main types of protein phosphorylation. This transfer is made possible through enzymes called tyrosine kinases. Tyrosine phosphorylation is one of the major means of cell signaling transduction in multiple pathophysiological conditions regulated by tyrosine kinase activities. In cancer, unregulated tyrosine kinase activity can drive tumor malignancy and formation by generating inappropriate proliferation and survival signals. Antibodies that specifically recognize phosphorylated tyrosine residues have proved to be invaluable to these studies. The anti-phosphotyrosine antibody (clone 3B6) developed by PTM Biolabs, Inc. provides an exceptionally sensitive tool for studying tyrosine phosphorylation and its kinase activities in biomedical and preclinic studies as well as high throughput drug discovery.

Cellular location

/

Images
Dot Blot

Blocking buffer: 5% NFDM/TBST
Primary Ab dilution: 1:1000
Primary Ab incubation condition: 2 hours at room temperature
Secondary Ab: Goat Anti-Mouse IgG H&L pAb (HRP Conjugate)
Immunogen peptide quantity: 4 ng, 20 ng, 100 ng
Exposure time: 60 s
The list of peptides is included in the table below.

WB

Blocking buffer: 5% NFDM/TBST
Primary Ab dilution: 1:1000
Primary Ab incubation condition: 2 hours at room temperature
Secondary Ab: Goat Anti-Mouse IgG H&L pAb (HRP Conjugate)
Lysate: (-) HeLa, (+) HeLa+sodium vanadate (1mM, 15mins)
Protein loading quantity: 20 μg
Exposure time: 60 s
Predicted band size: Multiple kDa
Observed band size: Multiple kDa

Research Use

For research use only, not for use in diagnostic procedures.

Recommended Products
  • View More Images(2)
    $ 300
    Anti-Phosphotyrosine Rabbit pAb
    Catalog #
    PTM-702
    Host
    Rabbit
    Clonality
    Polyclonal
    Conjugate
    Unconjugated
    Reactivity
    Human, Mouse, Rat
    Applications:
    WB IHC-P ICC/IF FC IAP IP ChIP mIHC-P
  • View More Images(4)
    $ 280
    Recombinant Rabbit Monoclonal
    Anti-Phosphotyrosine Rabbit mAb
    Catalog #
    PTM-702RM
    Host
    Rabbit
    Clonality
    Recombinant Monoclonal
    Conjugate
    Unconjugated
    Reactivity
    All
    Applications:
    WB IHC-P ICC/IF FC IAP IP ChIP mIHC-P
  • View More Images(1)
    $ 1,450
    Anti-Phosphotyrosine Antibody Conjugated Agarose Beads
    Catalog #
    PTM-703
    Host
    /
    Clonality
    /
    Conjugate
    Agarose
    Reactivity
    All
    Applications:
    WB IHC-P ICC/IF FC IAP IP ChIP mIHC-P
References (11)
  • TFAM loss induces nuclear actin assembly upon mDia2 malonylation to promote liver cancer metastasis
    Year 2022
    Journal EMBO JOURNAL
    Authors Qichao Huang, et al.
    Applications Unspecified
    Reactivity
  • New application of novel tetrazine derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents
    Year 2022
    Journal Future Medicinal Chemistry
    Authors Quan Zheng, et al.
    Applications Unspecified
    Reactivity
  • Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells
    Year 2021
    Journal JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
    Authors Yan Zhang, et al.
    Applications Unspecified
    Reactivity
  • Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors
    Year 2021
    Journal Future Medicinal Chemistry
    Authors Hao Jin, et al.
    Applications Unspecified
    Reactivity
  • Synthesis and Anti-Proliferation Activity Evaluation of Novel 2-Chloroquinazoline as Potential EGFR-TK Inhibitors
    Year 2021
    Journal CHEMISTRY & BIODIVERSITY
    Authors Quan Zheng, et al.
    Applications Unspecified
    Reactivity
  • Rab25 acts as an oncogene and participates in the regulation of aerobic glycolysis via PKM2 in gastric adenocarcinoma
    Year 2021
    Journal Translational Cancer Research
    Authors Tianyu Zheng, et al.
    Applications Unspecified
    Reactivity
  • Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment
    Year 2020
    Journal JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
    Authors Yi Le, et al.
    Applications Unspecified
    Reactivity
  • Enrichment of novel quinazoline derivatives with high antitumor activity in mitochondria tracked by its self-fluorescence
    Year 2019
    Journal EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    Authors Yaling Zhang, et al.
    Applications Unspecified
    Reactivity
  • Characterization of the Sperm Proteome and Reproductive Outcomes with in Vitro, Fertilization after a Reduction in Male Ejaculatory Abstinence Period *
    Year 2019
    Journal MOLECULAR & CELLULAR PROTEOMICS
    Authors Zi-Qi Shen, et al.
    Applications Unspecified
    Reactivity
  • Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFRwt-TK inhibitor
    Year 2019
    Journal JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
    Authors Yaling Zhang, et al.
    Applications Unspecified
    Reactivity
  • Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells
    Year 2017
    Journal EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
    Authors Li Chen, et al.
    Applications Unspecified
    Reactivity